Phase 3 Ovarian Cancer Trial, Recruiting NCT02429700 Sponsor: Beihua Kong Condition: Ovarian Cancer
Back to Ovarian Cancer

Phase 3 Ovarian Cancer Trial, Recruiting

NCT02429700
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a Chinese woman aged 65 or younger
  • You have been diagnosed with an ovarian stromal tumor (a specific type of ovarian tumor), confirmed by a tissue sample, including types such as granulosa cell tumor, Sertoli-Leydig cell tumor, or other related types (confirm with trial site for full list)
  • Your cancer has been newly diagnosed and is at a moderately advanced to advanced stage (stage IIA through IVB)
  • You have had surgery related to your diagnosis within the past 8 weeks
  • Your blood counts and organ function (liver, kidneys, and blood cells) meet certain healthy levels as measured by lab tests (confirm with trial site for specific values)
  • You are well enough to carry out daily activities at a reasonable level, as measured by a standard health scoring system
  • You are willing and able to sign a written consent form agreeing to take part

Who may not be able to join:

  • You have a serious or poorly controlled medical condition that makes surgery or chemotherapy unsafe for you
  • You have had an organ transplant or have a history of immune system disease
  • You have a history of serious mental illness or a condition affecting brain function
  • You have a history of drug misuse or substance abuse
  • You currently have or have previously had another type of cancer
  • You are currently taking part in another clinical trial
  • You are unwilling or unable to sign the consent form
  • You are unwilling or unable to follow the rules and schedule of the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 7 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Beihua Kong, MD. PhD., Qilu Hospital of Shandong University

Phone: +8618560081888

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Beihua Kong
Registry
ClinicalTrials.gov
Start date
1 April 2015
Est. completion
1 May 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Progression-free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov